Catalent delays filing of annual report

Catalent

30/08/2024 22:29

Aug 30 (Reuters) - Catalent  CTLT.N  said on Friday it
was unable to file its annual report with regulators on time as
it requires additional time to complete "certain processes".
    The contract drug manufacturer was expected to file the
report on Aug. 29.
    The company is awaiting the closing of the $16.5 billion
takeover deal signed in February by Novo Holdings, the
investment firm that has a controlling interest in Danish
drugmaker Novo Nordisk  NOVOb.CO .
    Catalent expects the deal to close towards the end of the
year.
    Catalent is a contractor that does fill-finish work, which
involves the filling and packaging of syringes and injection
pens in sterile conditions, including Novo Nordisk's blockbuster
drug Wegovy.
    The U.S. Federal Trade Commission in May sought more
information on the deal, after Novo Holdings prefiled an
application seeking the antitrust agency's nod.
    The company beat analysts' estimates for fourth-quarter
revenue on Thursday, helped by its biologics segment that
develops and manufactures cell and gene therapies.
    

 (Reporting by Sriparna Roy in Bengaluru; Editing by Maju
Samuel)
 ((Sriparna.Roy@thomsonreuters.com;))